SEARCH

Current Edition

ABBVIE

AbbVie keeps up dealmaking pace in neuroscience

Dive Brief: AbbVie announced Friday a new agreement with its longtime partner Gedeon Richter to research and develop dopamine-regulating treatments for neuropsychiatric diseases.   According …

Continue Reading →
ABBVIE

FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi

Dive Brief: The top-selling product for French pharmaceutical giant Sanofi now has two more competitors in the U.S. market, as the Food and Drug Administration …

Continue Reading →
ABBVIE

Biohaven to seek FDA approval for second migraine drug after study success

While a smaller biotech company, Biohaven has succeeded in a market led by large pharmaceutical firms like Lilly, AbbVie and, in the preventive treatment setting, …

Continue Reading →
ABBVIE

AbbVie’s blockbuster weighed down by safety concerns for a similar Pfizer drug

For years, AbbVie’s business has relied on Humira. One of the world’s top-selling medicines, Humira brought in close to $20 billion for AbbVie in each …

Continue Reading →
ABBVIE

Biohaven’s pipeline takes a hit as drug for rare neurological disease falls short in trial

Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales …

Continue Reading →
ABBVIE

In a first, FDA approves an ‘interchangeable’ biosimilar for diabetes

The promise of biosimilars — that competition would bring down the prices of complex biological drugs — hasn’t materialized in the U.S. in the way …

Continue Reading →
ABBVIE

Biopharmaceuticals Market Strongly guided by Companies like ABBVIE, AMGEN, BRISTOL

The market is expected to register a CAGR of 8.5% during the forecast period 2018 to 2023. North America dominates the market due to the …

Continue Reading →